Fig 6.

Meta-regression on risk of clinical fractures with baseline mean age as risk indicator, for antiresorptive agents (selective oestrogen receptor modulators, bisphosphonates, and denosumab) versus placebo. Based on restricted maximum likelihood based meta-regression for association between (log risk ratio) clinical fractures and mean age. Bisphosphonates versus placebo are indicated by purple dots and selective oestrogen receptor modulators versus placebo by yellow dot; colours do not reflect the applied model and are only for illustrative purposes. Meta-regression was done on log risk ratio scale, but for ease of interpretation, the back transformed risk ratio is shown. Identification number in figure, trial name, and reference: 3=FIT1 (Fracture Intervention Trial 1)¹⁸; 4=HORIZON-PFT (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial)¹⁹; 7=FIT2 (Fracture Intervention Trial 2)²⁰; 11=ZEST (Zoledronic acid in frail Elders to STrengthen bone)⁸⁵; 12=ACTRN12607000576426⁸⁷; 15=Hosking 1998²¹; 18=IBAN IV¹⁸³; 20=ACTRN1260900593235¹³⁹; 50=ACTRN12605000278639⁸⁸; 51=Hosking 2003⁹³; 52=Greenspan 2003⁸⁶; 53=Downs 2000⁷³; 55=Miller 2008¹²¹; 78=Bell 2002⁴⁴; 79=Bone 2000⁴⁹; 82=McClung 2009¹⁸²; 93=NCT00271713¹⁶⁵